CorPath GRX Given the Royal Treatment by Countess of Wessex

Posted by Corindus Staff
December 10, 2019
countess of wessex toronto visit

The Royal Family’s Countess of Wessex, Sophie Helen Rhys-Jones, visited Toronto in November for the second part of her North American trip. With her strong personal interest in health and wellness, along with assisting people with disabilities, the countess visited both Toronto Western Hospital and Toronto General Hospital. Both hospitals specialize in cardiology along with the treatment of strokes and transplants.


The countess’ visit to Toronto Western happened to coincide with a groundbreaking medical procedure—a physician performed the world’s first successful robotic-assisted brain procedure utilizing our CorPath GRX System. The landmark aneurysm coiling procedure marked a significant milestone as Corindus strives to utilize robotics as a new treatment paradigm that can treat heart attack and stroke patients from a remote location*.


As previously announced, the procedure was performed by a team led by Dr. Vitor Mendes Pereira, a neurosurgeon and neuroradiologist at the Toronto Western Hospital and Krembil Brain Institute in Canada. Prior to the procedure on the female patient, Dr. Pereira performed a rehearsal procedure on a Biomodex 3D-printed flow model of the specific anatomy of the patient, which provided Dr. Pereira an opportunity to gain comfortability with the novel procedure.  


In her visit, the countess learned firsthand about the hospital’s sharp focus on technology and innovation, including robotic-assisted procedures. The countess was seen on video sitting at the controls of CorPath GRX as a technician demonstrated how the device works, and its enhanced precision over manual procedures.


Fortunately, no patients needed the countess to intervene on them, but the staffs at both hospitals were honored to host her and share the latest developments in robotic-assisted procedures.


Read more about the Countess of Wessex's trip to Toronto


*Remote capabilities are currently under development; it is not for sale. Its future availability cannot be guaranteed. CorPath GRX for use in neurovascular interventions is currently under development; it is not for sale in the U.S.A. Its future availability cannot be guaranteed.




Link to my Twitter Page
Link to my Linkedin Page
Link to my Facebook Page
Link to my Rss Page

Recent Posts